Universal genetic screening uncovers a novel presentation of an sdhaf2 mutation
Casey, Mary B.
MetadataShow full item record
This item's downloads: 0 (view details)
Casey, Ruth; Garrahy, Aoife; Tuthill, Antoinette; O'Halloran, Domhnall; Joyce, Caroline; Casey, Mary B. O'Shea, Paula; Bell, Marcia (2014). Universal genetic screening uncovers a novel presentation of an sdhaf2 mutation. The Journal of Clinical Endocrinology & Metabolism 99 (7), E1392-E1396
Context: Hereditary pheochromocytoma/paraganglioma (PC/PGL) accounts for up to 60% of previously considered sporadic tumors. Guidelines suggest that phenotype should guide genetic testing. Next-generation sequencing technology can simultaneously sequence 9 of the 18 known susceptibility genes in a timely, cost-efficient manner. Objective: Our aim was to confirm that universal screening is superior to targeted testing in patients with histologically confirmed PC and PGL. Methods: In two tertiary referral hospitals in Ireland, NGS was carried out on all histologically confirmed cases of PC/PGL diagnosed between 2004 and 2013. The following susceptibility genes were sequenced: VHL, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, and MAX. A multiplex ligation-dependent probe amplification analysis was performed in VHL, SDHB, SDHC, SDHD, and SDHAF2 genes to detect deletions and duplications. Results: A total of 31 patients were tested, 31% (n = 10) of whom were found to have a genetic mutation. Of those patients with a positive genotype, phenotype predicted genotype in only 50% (n = 5). Significant genetic mutations that would have been missed in our cohort by phenotypic evaluation alone include a mutation in TMEM127, two mutations in SDHAF2, and two mutations in RET. Target testing would have identified three of the latter mutations based on age criteria. However, 20% of patients (n = 2) would not have satisfied any criteria for targeted testing including one patient with a novel presentation of an SDHAF2 mutation. Conclusion: This study supports the value of universal genetic screening for all patients with PC/PGL.